147 related articles for article (PubMed ID: 34298699)
1. Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer.
Lu YL; Wu MH; Lee YY; Chou TC; Wong RJ; Lin SF
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298699
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of adavosertib therapy against anaplastic thyroid cancer.
Lu YL; Huang YT; Wu MH; Chou TC; J Wong R; Lin SF
Endocr Relat Cancer; 2021 Apr; 28(5):311-324. PubMed ID: 33769310
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic inhibition of ATR in differentiated thyroid cancer.
Lin SF; Lee YY; Wu MH; Lu YL; Yeh CN; Chen WY; Chou TC; Wong RJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902083
[TBL] [Abstract][Full Text] [Related]
4. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
Chen J; Jia X; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Biochem Pharmacol; 2021 Jun; 188():114494. PubMed ID: 33684390
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
6. Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.
Roering P; Siddiqui A; Heuser VD; Potdar S; Mikkonen P; Oikkonen J; Li Y; Pikkusaari S; Wennerberg K; Hynninen J; Grenman S; Huhtinen K; Auranen A; Carpén O; Kaipio K
Front Oncol; 2022; 12():954430. PubMed ID: 36081565
[TBL] [Abstract][Full Text] [Related]
7. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Bell HL; Blair HJ; Singh M; Moorman AV; Heidenreich O; van Delft FW; Lunec J; Irving JAE
Cancer Cell Int; 2023 Sep; 23(1):202. PubMed ID: 37715172
[TBL] [Abstract][Full Text] [Related]
8. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
[TBL] [Abstract][Full Text] [Related]
10. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
[TBL] [Abstract][Full Text] [Related]
11. Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.
Pitts TM; Simmons DM; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Tentler JJ; Cittelly D; Ormond DR; Messersmith WA; Eckhardt SG; Diamond JR
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32204315
[TBL] [Abstract][Full Text] [Related]
12.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
13. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
14. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
15. Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
Endocr Relat Cancer; 2018 Oct; 25(10):853-864. PubMed ID: 29895526
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer.
Jing C; Gao Z; Wang R; Yang Z; Shi B; Hou P
Am J Cancer Res; 2017; 7(4):903-912. PubMed ID: 28469962
[TBL] [Abstract][Full Text] [Related]
17. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
19. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
